Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
05 Settembre 2024 - 2:00PM
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced that Madhavan (Madhu)
Balachandran was elected to Replimune’s Board of Directors at the
Company’s annual meeting of stockholders.
“We are thrilled to welcome Madhu to Replimune’s Board of
Directors,” said Sushil Patel, Ph.D., Chief Executive Officer of
Replimune. “Madhu is an accomplished life sciences industry
executive with decades of valuable experience in commercial
development, manufacturing and operations. We look forward to
working with Madhu as we continue to prepare for commercialization
and believe his addition will further strengthen our Board.”
Mr. Balachandran is a biopharma industry executive and has more
than 40 years of experience in manufacturing and operations. He was
previously with Amgen Inc., where he served as Executive Vice
President of Operations, overseeing global operations and reporting
directly to the CEO. Mr. Balachandran held senior operations
positions at Burroughs Wellcome Co. Mr. Balachandran holds an MBA
from East Carolina University, a MS in Chemical Engineering from
the State University of New York at Buffalo, and a bachelor’s
degree in chemical engineering from The Indian Institute of
Technology, Mumbai.
About Replimune Replimune Group,
Inc., headquartered in Woburn, MA, was founded in 2015 with
the mission to transform cancer treatment by pioneering the
development of a novel portfolio of oncolytic immunotherapies.
Replimune’s proprietary RPx platform is based on a potent HSV-1
backbone intended to maximize immunogenic cell death and the
induction of a systemic anti-tumor immune response. The RPx
platform is designed to have a unique dual local and systemic
activity consisting of direct selective virus-mediated killing of
the tumor resulting in the release of tumor derived antigens and
altering of the tumor microenvironment to ignite a strong and
durable systemic response. The RPx product candidates are expected
to be synergistic with most established and experimental cancer
treatment modalities, leading to the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Investor InquiriesChris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Grafico Azioni Replimune (NASDAQ:REPL)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Replimune (NASDAQ:REPL)
Storico
Da Feb 2024 a Feb 2025